Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $84.83. According to TipRanks.com, Walton is ranked #6629 out of 9418 analysts. Sanofi has an analyst consensus of ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Trump's looming tariff threats have prompted several announcements, even as the EU pleads for more investment in Europe.

Sanofi and Eli Lilly. We raised our fair value estimate for Novo Nordisk to DKK 640 per share from DKK 600 following a solid management outlook for 2025 that likely reflects stronger growth in GLP ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...